• FY26 results met expectations with increased revenue and profit after tax
• Significant year for new contracts and major renewals
• AI and digital pathology developments drive future growth

Pro Medicus CEO Dr. Sam Hupert discusses FY26 results, noting that the company met expectations with increased revenue and profit after tax. FY26 was the company's second-biggest year for new contracts, with six major renewals and numerous implementations. The company is well-positioned to benefit from AI, particularly in diagnostic imaging, with its platform used by 11% of the US market. Additionally, the company is developing a digital pathology solution and an AI-driven reporting platform, both of which are expected to generate additional revenue streams. The company's strong performance is attributed to trends such as the adoption of cloud solutions, increased contract values, and a growing market recognition of Pro Medicus's unique technology.

NPAT increased by more than 32% on a constant currency basis

Pro Medicus is well-positioned to benefit from AI and digital pathology, with a strong pipeline and significant renewals.